Sign In

Alexander Belcredi

Entrepreneur & Manager | BioNTech R&D Austria

Alexander Belcredi, Start-up Mentor at Creative Destruction Lab

Alexander Belcredi is a seasoned biotech entrepreneur who has been working in the pharmaceutical industry for over a decade.45 He is currently a mentor at the Creative Destruction Lab, a seed-stage program for massively scalable, science-based companies.24

Some key facts about Alexander Belcredi:

  • He is the former Managing Director of BioNTech R&D Austria26
  • He co-founded PhagoMed, a start-up developing synthetic lysin technology for precision antimicrobial treatments. PhagoMed was acquired by BioNTech in 202113
  • PhagoMed was accelerated by EIT Health's Gold Track program, which Alexander Belcredi thanked for supporting the company to refine its pipeline, platform and business model3
  • He has over 500+ connections on LinkedIn under the username alexanderbelcredi5
  • His email address is available on RocketReach, a people search engine6

As a mentor at Creative Destruction Lab, Alexander Belcredi provides guidance and expertise to help science-based start-ups achieve commercial success.24 His experience founding and leading PhagoMed makes him well-positioned to advise other biotech entrepreneurs navigating the challenges of building a company in this space.13

Highlights

Oct 25 · linkedin

The Hype vs. The Hard Truth: Phage Therapy against S. aureus is not straightforward

We are very excited to share our latest paper highlighting the intricacies of phage therapy against Staphylococcus aureus. The medical need for novel therapies against S. aureus (incl. MRSA/MSSA) is huge; but phage therapy may not be the straightforward answer we hoped for. The findings described in this article led us to stop our phage work already in 2020 and re-focus on phage-derived #endolysins as anti-bacterials. By publishing the technical issues we had with phages, we hope to underscore the challenges that need to be addressed. Big thanks to our brilliant team incl. David Sáez Moreno, Michele Mutti, Marcela Restrepo, Zehra Visram, Grégory Resch and of course Lorenzo Corsini Read the full paper here: https://lnkd.in/dbfteBax #endolysins #Biotech #PhageTherapy #StaphylococcusAureus #AMR #ResearchChallenges

Nov 19 · linkedin

#Location matters. #Vienna and #Austria are underrated biotech destinations and its worth to put a spotlight on the location that allowed Lorenzo Corsini and myself to build a strong biotech company.   What makes Vienna/Austria so great for biotech:

  • Public co-funding programs are fantastic. Biotech is high-risk, high-reward. Public funds can help bridge the tough economics – and Austria has awesome support programs. FFG Österreichische Forschungsförderungsgesellschaft mbH provided “pay-as-you-go” co-funding for our programs from day 1 that enabled us to get the most value out of the private investments that seeded our company. The FFG also has a fantastic biotech team in place that helps to navigate the grant programs. Austria Wirtschaftsservice provides Pre-Seed and Seed co-funding (we got a seed grant back in 2018) that again help scale the private investment. Together these programs ensure a big “bang for the buck” for the crucial private investments.
  • Talent is ubiquitous. Vienna has world-class research institutes that attract thousands of high-quality students, PhDs and Post-Docs every year. We have consistently been able to recruit top-class talent from right in front of our door step – and the vibrant scientific scene makes for exciting collaborations and idea exchanges
  • Vienna is a great city to live and work in. Vienna has consistently taken the top prizes for “best quality of life”. Vienna is safe, clean, efficient and – maybe most importantly for a European capital – still very much affordable. Quite a few of our colleagues moved to Vienna to join PhagoMed which is a great testament to the ability of Vienna to attract top talent.
  • Finally, the Vienna BioCenter (VBC) is a great home. The VBC is home to 4 world-class research institutes, ~40 biotech companies and a university campus. Apart from thousands of students, more than 2,500 researchers work here and we have been a proud member of the VBC from the beginning – benefitting from collaborations with other Vienna BioCenter companies, the ability to recruit talent from the institutes and the access to shared facilities with cutting-edge high-tech equipment that we could not have afforded as a young biotech. See the slide below for some impressive statistics on the VBC in 2021!   Nothings perfect. Vienna could use more lab space, more biotech focused VCs and an even bigger “big pharma” footprint. But on balance: it’s an awesome place to build a biotech! 😊

LISAvienna - Life Science Austria Vienna

Related Questions

What is Alexander Belcredi's background in the biotech industry?
How did Alexander Belcredi transition from PhagoMed to BioNTech?
What specific startups has Alexander Belcredi mentored at Creative Destruction Lab?
What are some notable achievements of Alexander Belcredi in the field of phage therapy?
How does Alexander Belcredi's experience at BioNTech influence his mentorship at CDL?
Alexander Belcredi
Alexander Belcredi, photo 1
Alexander Belcredi, photo 2
Add to my network

Location

Austria